Summary
William J. Link, a director at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), completed the sale of 12,490 common shares on March 16, 2026, resulting in proceeds of approximately $859,818. The disposals were carried out in three tranches and implemented pursuant to a previously adopted Rule 10b5-1 trading plan dated September 8, 2025.
Transaction details
- First block: 3,629 shares sold at a weighted average price of $68.09, producing $247,097 in proceeds.
- Second block: 8,378 shares sold at a weighted average price of $69.03, producing $578,332 in proceeds.
- Third block: 493 shares sold at a weighted average price of $69.75, producing $34,389 in proceeds.
Taken together, these three transactions total 12,490 shares sold for roughly $859,818. Following the trades, Link is recorded as directly owning 116,332 shares of Tarsus Pharmaceuticals common stock. The sales were executed under a pre-arranged Rule 10b5-1 plan that Link adopted on September 8, 2025.
Company financial backdrop
Separately, Tarsus Pharmaceuticals reported a strong set of results for the fourth quarter of 2025 and for the full year. The company cited net product sales of $151.7 million for the quarter and $451.4 million for the year, driven by its flagship product, XDEMVY. Management characterized these outcomes as a notable period of growth for the business.
Despite the robust financial performance, the company’s stock experienced a minor decline in aftermarket trading. The reporting notes this modest share movement as an indication of nuanced investor sentiment following the announcement of results and the insider transactions.
Outlook and market attention
These developments - a sizable insider sale conducted under a trading plan and recent strong revenue and profitability metrics - are likely to keep Tarsus Pharmaceuticals under close observation by investors and analysts as the company navigates the evolving pharmaceutical market. The available disclosures do not attribute causes for the aftermarket share movement beyond noting its existence.
Note: All transaction amounts, dates, and financial results referenced above reflect the company disclosures and the filing details provided by Tarsus Pharmaceuticals.